Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Letue35 

Discuss Cytokinetics Inc.

Cytokinetics Inc.

WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

53,50 €
-5,17 %

Einschätzung Buy
Rendite (%) 47,33 %
Kursziel 16,00
Veränderung
Endet am 16.05.20

Buy with target price 16.0

Einschätzung Sell
Rendite (%) 67,96 %
Kursziel 16,00
Veränderung
Endet am 04.11.21

Sell with target price 16.0

Einschätzung Buy
Rendite (%) 63,79 %
Kursziel 54,33
Veränderung
Endet am 01.03.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $58.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 71,39 %
Kursziel 45,28
Veränderung
Endet am 02.03.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $56.00 to $48.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 64,40 %
Kursziel 74,81
Veränderung
Endet am 06.03.24

Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at Mizuho. They set a "buy" rating and a $80.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 110,12 %
Kursziel 45,16
Veränderung
Endet am 31.03.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at HC Wainwright from $56.00 to $49.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 87,86 %
Kursziel 56,02
Veränderung
Endet am 03.04.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target lowered by analysts at UBS Group AG from $67.00 to $61.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 70,38 %
Kursziel 44,48
Veränderung
Endet am 04.08.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 77,15 %
Kursziel 54,39
Veränderung
Endet am 04.08.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $60.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 77,15 %
Kursziel 54,39
Veränderung
Endet am 04.08.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 92,95 %
Kursziel 53,00
Veränderung
Endet am 15.08.24

Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $58.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 83,12 %
Kursziel 56,68
Veränderung
Endet am 20.10.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 83,12 %
Kursziel 54,79
Veränderung
Endet am 20.10.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at HC Wainwright from $49.00 to $58.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 61,14 %
Kursziel 55,05
Veränderung
Endet am 01.11.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $58.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 72,16 %
Kursziel 61,81
Veränderung
Endet am 07.11.24

Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at B. Riley. They set a "buy" rating and a $66.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) 69,30 %
Kursziel 46,68
Veränderung
Endet am 09.11.24

Cytokinetics, Incorporated (NASDAQ: CYTK) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $50.00 price target on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -26,71 %
Kursziel 84,57
Veränderung
Endet am 27.12.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at HC Wainwright from $58.00 to $94.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -27,21 %
Kursziel 97,23
Veränderung
Endet am 27.12.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Needham & Company LLC from $60.00 to $108.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat

Einschätzung Buy
Rendite (%) -29,61 %
Kursziel 77,64
Veränderung
Endet am 28.12.24

Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Truist Financial Co. from $60.00 to $86.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat